Summary
To improve the pharmacokinetic profile of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) an N-terminal specific pegylation was performed to generate pegylated TRAIL (PEG-TRAIL). In in vitro experiments, we found that although PEG-TRAIL was slightly less efficient than recombinant TRAIL in promoting leukemic cell apoptosis, it showed an improved ability to promote migration of bone-marrow mesenchymal stem cells and to elicit the ERK1/2 intracellular signal transduction pathway. Overall, these data suggest that TRAIL pegylation retains, or even enhances, the biological activities of TRAIL relevant for its therapeutic applications.
This is a preview of subscription content, log in via an institution to check access.
References
Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340
Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135
Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15:42–48
Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of Dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non–small-cell lung cancer. J Clin Oncol 28:1527–1533
Kelley SK, Harris LA, Xie D et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38
Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandon E (2004) Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 32:1230–1238
Mirandola P, Ponti C, Gobbi G et al (2004) Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity. Blood 104:2418–2424
Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G (2005) TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105:3413–3419
Re MC, Zauli G, Gibellini D et al (1993) Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS 7:1049–1055
Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti-Brodano G (1995) HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retrovir 11:1039–1048
Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965–1974
Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S (1996) Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 271:22961–22964
Gibellini D, Bassini A, Pierpaoli S et al (1998) Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891–3898
Secchiero P, Corallini F, Pandolfi A et al (2006) An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236–2244
Secchiero P, Melloni E, Corallini F et al (2008) Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 26:2955–2963
Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221
Veronese F, Pasut GF, Drioli S, Bonora GM (2010) Poly(ethylene glycol)-protein, peptide and enzyme conjugates. In: Reddy LH, Couvreur P (eds) Macromolecular anticancer therapeutics. Springer, New York, pp 265–291
Bonora GM, Drioli S (2009) Reactive PEGs for protein conjugation. In: Veronese F (ed) PEGylated protein drugs: basic science and clinical applications. Birkhause Verlag AG (CH), pp 33–45
Yamamoto Y, Tsutsumi Y, Yoshioka Y et al (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21:546–552
Shaunak S, Godwin A, Choi JW et al (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2:312–313
Chae SY, Kim TH, Park K et al (2010) Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 9:1719–1729
Acknowledgements
This study was supported by Carife Foundation and by a grant from “Programma di Ricerca Regione-Università 2007/2009” (Regione Emilia Romagna) (to PS).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gonelli, A., Radillo, O., Drioli, S. et al. Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Invest New Drugs 30, 828–832 (2012). https://doi.org/10.1007/s10637-010-9599-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9599-8